cor2ed
engage checkpoint medical linkedin twitter
bg

Antibody-drug conjugates in urothelial cancer

Antibody-drug conjugates in urothelial cancer

Prof. Sandy Srinivas

Prof. Sandy Srinivas takes a look at antibody-drug conjugates (ADCs) in urothelial cancer.
Image of Sandy Srinivas
Prof. Sandy Srinivas

Medical Oncologist

Stanford University Medical Center

United States (US)

preview next

time Expert View | open 5 min | Jul 2020

temporal

I agree that this educational programme:

Prof. Sandy Srinivas takes a look at antibody-drug conjugates (ADCs) in urothelial cancer, in particular the first-in-class drug, Enfortumab Vedotin, and the pivotal trial resulting in registration together with promising data in combination with checkpoint inhibitors as well as another ADC, Sacituzumab Govitecan, which targets Trop-2. Prof. Srinivas also discusses the development of ADCs for other GU tumour types.

GU CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from AstraZeneca, Bayer and Eisai Europe Limited.

Other programmes of interest